In Part 2 of this series, we explore where employers have more leverage in pharmacy benefits than they realize—and how to apply it deliberately in the best interest of plan participants.
Why pharmacy transparency is becoming a C-suite issue
In Part 1 of a two-part series, we examine why pharmacy transparency has become a C-suite issue—and what it means for fiduciary oversight.
Voluntary benefits are becoming the next ERISA fee battlefield
A new wave of ERISA litigation is calling attention to voluntary benefits—an area many employers have long viewed as low-risk. In this piece, Andy Clonts explains why voluntary programs are drawing scrutiny, how compensation structures and loss ratios can create fiduciary exposure, and why plan sponsors should revisit the governance and financial mechanics behind these offerings before regulators or plaintiffs do.